Transforming growth factor beta inhibitors - Pipeline Insight, 2024

Transforming growth factor beta inhibitors - Pipeline Insight, 2024

DelveInsight’s, “Transforming growth factor beta inhibitors- Pipeline Insight, 2024” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs based on Transforming growth factor beta inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Transforming growth factor beta inhibitors Understanding

Transforming growth factor beta inhibitors: Overview

Transforming growth factor-β (TGF-β) regulates cell growth and differentiation, apoptosis, cell motility, extracellular matrix production, angiogenesis, and cellular immunity. It has a paradoxical role in cancer. In the early stages it inhibits cellular transformation and prevents cancer progression. In later stages TGF-β plays a key role in promoting tumor progression through mainly 3 mechanisms: facilitating epithelial to mesenchymal transition, stimulating angiogenesis and inducing immunosuppression. As a result of its opposing tumor promoting and tumor suppressive abilities, TGF-β and its pathway has represented potential opportunities for drug development and several therapies targeting the TGF-β pathway have been identified. This review focuses on identifying the mechanisms through which TGF-β is involved in tumorigenesis and current therapeutics that are under development.

Transforming growth factor beta inhibitors Emerging Drugs Chapters

This segment of the Transforming growth factor beta inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Transforming growth factor beta inhibitors Emerging Drugs

• Trabedersen: Oncotelic

Trabedersen (OT-101) is a single-stranded phosphorothioate antisense oligodeoxynucleotide (18-mer) targeting the human TGF-β2 messenger RNA. Ready for registration trials--Over 200 patients treated across 6 clinical trials. It has Potential for breakthrough designation for early approval. It is in phase III stage of development.

• KER-050: Keros Therapeutics

KER-050, is an engineered ligand trap comprised of a modified ligand-binding domain of the TGF-β receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. KER-050 is designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-β family of proteins to promote hematopoiesis. It is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis.

• STP705: Sirnaomics

STP705 is delivered intradermally to the tumor site resulting in localized silencing of TGF-b1 and Cox-2, killing of the tumor cells and a reduction in tumor size. It is currently in phase II stage of development.

Further product details are provided in the report……..

Transforming growth factor beta inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Transforming growth factor beta inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Transforming growth factor beta inhibitors

There are approx. 90+ key companies which are developing the therapies based on Transforming growth factor beta inhibitors. The companies which have their drug candidate based on Transforming growth factor beta inhibitors in the most advanced stage, i.e. phase III include Oncotelic and others

• Phases

DelveInsight’s report covers around 90+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Transforming growth factor beta inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Transforming growth factor beta inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Transforming growth factor beta inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Transforming growth factor beta inhibitors drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Transforming growth factor beta inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Sirnaomics announced that the Office of Orphan Product Development division of the FDA has granted orphan drug designation to its leading therapeutic candidate, STP705, for the treatment of Hepatocellular Carcinoma (HCC).
• In August 2017, Sirnaomics stated that the Office of Orphan Product Development division of the USA FDA has granted Orphan Drug Designation to its leading therapeutic candidate, STP705, for the treatment of Primary Sclerosing Cholangitis (PSC).
• Trabedersen (OT-101) has strong Patent protection until 2037 and has received Orphan designation granted for three tumor indications in US & EU.

Transforming growth factor beta inhibitors Report Insights

• Transforming growth factor beta inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Transforming growth factor beta inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

• What are the current treatment options available based on the Transforming growth factor beta inhibitors?
• How many companies are developing therapies by working on Transforming growth factor beta inhibitors?
• What are the principal therapies developed by these companies in the industry?
• How many therapies are developed by each company for Transforming growth factor beta inhibitors to treat disease condition?
• How many emerging therapies are in early-stage, mid-stage, and late stage of development for Transforming growth factor beta inhibitors?
• Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other treatments?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Transforming growth factor beta inhibitors therapies?
• Which are the dormant and discontinued products and the reasons for the same?
• What is the unmet need for current therapies developed based on this mechanism of action?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Transforming growth factor beta inhibitors and their status?
• What are the results of the clinical studies and their safety and efficacy?
• What are the key designations that have been granted for the emerging therapies for Transforming growth factor beta inhibitors?
• How many patents are granted and pending for the emerging therapies of Transforming growth factor beta inhibitors?

Key Players

• Oncotelic
• Jiangsu Hengrui Medicine Co
• Bristol-Myers Squibb/Rigel.
• Biogen Idec
• Genentech
• Tilos Therapeutics
• Eli Lilly and Company

Key Products

• Trabedersen
• SHR 1701
• Research programme: transforming growth factor beta receptor kinase inhibitors
• Research programme: transforming growth factor beta-1 receptor antagonists
• Anti-TGF-beta monoclonal antibody 2G7
• TL 02
• TL 03
• LY 3200882